- Home
- PGY vs PRAX Comparison
PGY vs PRAX Comparison
Compare PGY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGY | PRAX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PGY | PRAX |
|---|---|---|
| Price | $22.76 | $272.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $39.86 | ★ $349.79 |
| AVG Volume (30 Days) | ★ 2.7M | 1.1M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,245,946,000.00 | $7,463,000.00 |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $17.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 28.33 | ★ 364.98 |
| 52 Week Low | $8.27 | $26.70 |
| 52 Week High | $44.99 | $282.99 |
Technical Indicators
Market Signals| Indicator | PGY | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 69.29 |
| Support Level | $21.13 | $262.31 |
| Resistance Level | $24.07 | $282.99 |
| Average True Range (ATR) | 1.40 | 16.76 |
| MACD | -0.00 | 1.78 |
| Stochastic Oscillator | 36.03 | 90.59 |
Price Performance
Historical ComparisonAbout PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.